| Drug Name |
Dexrazoxane |
| Drug ID |
BADD_D00633 |
| Description |
An antimitotic agent with immunosuppressive properties. Dexrazoxane, the (+)-enantiomorph of razoxane, provides cardioprotection against anthracycline toxicity. It appears to inhibit formation of a toxic iron-anthracycline complex. [PubChem]
The Food and Drug Administration has designated dexrazoxane as an orphan drug for use in the prevention or reduction in the incidence and severity of anthracycline-induced cardiomyopathy. |
| Indications and Usage |
For reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin hydrochloride dose of 300 mg/m^2 and would benefit from continued doxorubicin therapy. Also approved for the treatment of extravasation from intravenous anthracyclines. |
| Marketing Status |
Prescription |
| ATC Code |
V03AF02 |
| DrugBank ID |
DB00380
|
| KEGG ID |
D03730
|
| MeSH ID |
D064730
|
| PubChem ID |
71384
|
| TTD Drug ID |
D07XVN
|
| NDC Product Code |
67457-208; 33656-0001; 0143-9248; 45562-1119; 54893-0097; 67457-207; 50384-0200; 0143-9247 |
| Synonyms |
Dexrazoxane | Razoxane, (S)-Isomer | Cardioxane | Cardioxan | Zinecard | ICRF-187 | ICRF 187 | ICRF187 | NSC-169780 | NSC 169780 | NSC169780 | ADR-529 | ADR 529 | ADR529 | Dexrazoxane Hydrochloride | Hydrochloride, Dexrazoxane | Razoxane, (S)-Isomer, Hydrochloride |
